Stamaril

Stamaril is a live, attenuated yellow fever vaccine derived from the 17D-204 strain. It helps provide immunity against yellow fever virus for travelers and at-risk populations. This vaccine is administered via injection and is widely used for pre-exposure prophylaxis. Short-term protection begins within 10 days of vaccination.

Stamaril is used to prevent yellow fever, a viral infection spread by infected mosquitoes. It is recommended for travelers visiting regions where yellow fever is endemic, as well as for laboratory workers handling the virus. The vaccine works by stimulating the immune system to produce antibodies against the yellow fever virus. It is also used for routine immunization in countries where the disease is common.

After vaccination, the body begins building immunity against the yellow fever virus. Some individuals may experience mild effects such as redness, swelling, or pain at the injection site. Low-grade fever, headache, or muscle aches can occur but typically resolve within a few days. These effects indicate the vaccine is prompting an immune response.

Stamaril should be stored and handled according to vaccine guidelines to maintain its effectiveness. It is important to inform healthcare providers of any allergies, especially to eggs or previous vaccine components. Pregnant or breastfeeding individuals should consult a healthcare professional before receiving this vaccine. Avoid vaccination if experiencing a fever or acute illness.

Stamaril may interact with immunosuppressive therapies, including corticosteroids or chemotherapy, potentially reducing vaccine effectiveness. Blood tests or other vaccines should be administered at least 4 weeks apart to avoid interference. Immunosuppressed individuals may require additional evaluation before receiving this live vaccine. Always disclose all medications and conditions to your healthcare provider.